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The stress regulator FKBP51: a novel and promising
druggable target for the treatment of persistent
pain states across sexes
Maria Maiaru`a, Oakley B. Morgana, Tianqi Maob, Michaela Breitsamerc, Harry Bambera, Max Po¨hlmannd,
Mathias V. Schmidtd, Gerhard Winterc, Felix Hauschb, Sandrine M. Ge´rantona,*
Abstract
It is well established that FKBP51 regulates the stress system by modulating the sensitivity of the glucocorticoid receptor to stress
hormones. Recently, we have demonstrated that FKBP51 also drives long-term inflammatory pain states in male mice by modulating
glucocorticoid signalling at spinal cord level. Here, we explored the potential of FKBP51 as a newpharmacological target for the treatment
of persistent pain across the sexes. First, we demonstrated that FKBP51 regulates long-term pain states of different aetiologies
independently of sex. Deletion of FKBP51 reduced themechanical hypersensitivity seen in joint inflammatory and neuropathic pain states
in female andmalemice. Furthermore, FKBP51 deletion also reduced the hypersensitivity seen in a translational model of chemotherapy-
induced pain. Interestingly, these 3 pain states were associated with changes in glucocorticoid signalling, as indicated by the increased
expression, at spinal cord level, of theglucocorticoid receptor isoformassociatedwithglucocorticoid resistance,GRb, and increased levels
of plasma corticosterone. These pain states were also accompanied by an upregulation of interleukin-6 in the spinal cord. Crucially, we
were able to pharmacologically reduce the severity of the mechanical hypersensitivity seen in these 3 models of persistent pain with the
unique FKBP51 ligand SAFit2.When SAFit2 was combinedwith a state-of-the-art vesicular phospholipid gel formulation for slow release,
a single injection of SAFit2 offered pain relief for at least 7 days. We therefore propose the pharmacological blockade of FKBP51 as a new
approach for the treatment of persistent pain across sexes, likely in humans as well as rodents.
Keywords: FKPB51, Dorsal horn, Glucocorticoid receptor, Glucocorticoid signalling, Persistent pain, Stress, Interleukin-6,
Corticosterone, Pharmacological inhibition, Paclitaxel, Vesicular phospholipid gel
1. Introduction
The FK506 binding protein 51 (FKBP51) is important for the
regulation of the stress response, and polymorphisms of the
FKBP51-encoding gene, FKBP5, have been associated with
atypical stress axis reactivity, with high levels of FKBP51 protein
associatedwith ahyperreactive stresspathwayoften seen inpatients
with depression.5,43 Supporting these observations, deletion of
FKBP5 in mice leads to a reduction in corticosterone secretion and
anxiety-related behaviours.17,18 FKBP51 is a co-chaperone that
changes folding and activity of other proteins. It modulates the stress
axis, also called the hypothalamic–pituitary–adrenal (HPA) axis,
through binding of the steroid complex and inhibition of the
glucocorticoid receptor (GR) function.43 Although it remains unclear
whether FKBP51 binding to the steroid complex directly inhibits GR
function,12 by regulating GR signalling FKBP51 can modulate the
actions of glucocorticoids, including the expression of
glucocorticoid-responsive genes and the GR-mediated negative
feedback of the HPA axis.43
Traumatic events are powerful stressors that can activate the
HPA axis and thereby are likely to contribute to the development
of persistent posttraumatic pain in vulnerable individuals.13,23,29
Supporting this hypothesis, variations in FKBP5 associated with
enhanced induction of FKBP5mRNA by cortisol and reduced GR
sensitivity4,5 were associated with increased musculoskeletal
pain after motor vehicle collision or sexual assault.7 Interestingly,
the association between the reported pain and the FKBP5 gene
variations was stronger 6 weeks after trauma than immediately
after trauma, suggesting that FKBP5wasmore likely to contribute
to persistent than acute pain states.7
Consistent with these findings, we have recently demonstrated
that FKBP51 is expressed in the rodent dorsal horn where it plays
a key role in the full development and maintenance of chronic joint
inflammatory pain,15,21 but has no effect on acute pain responses.
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FKBP5knock-out (KO)malemicewith an inflamed joint had reduced
pain compared with their wild-type (WT) littermates, and inhibition of
FKBP51 at spinal level, using siRNA, significantly attenuated
preexisting joint inflammatory pain. The expression of FKBP51 was
significantly reduced in the dorsal horn by intrathecal delivery of the
siRNA but left intact in dorsal root ganglia, indicating that FKBP51
expressed in dorsal root ganglia was unlikely to contribute to the
maintenance of the pain state. Moreover, FKBP51 modulation of
long-lasting mechanical hypersensitivity occurred through the
regulation of GR signalling,21 a signalling pathway previously shown
to regulate the hypersensitivity seen in long-termpain states at spinal
cord level.33,39,40 Finally, the deletion of FKBP51 was associated
with a reduced expression at spinal cord level of the cytokine
interleukin-6 (IL6), which is upregulated in chronic pain states44 and
under transcriptional control of GR.27,38
Here, we have used molecular and pharmacological tools to
investigate the regulation of permanent pain states of different
aetiology by FKBP51, in both male and female mice. It has been
suggested that the mechanisms of development of chronic pain
states differed between sexes, implying a potential need for
different strategies to address chronic pain in men and
women.2,32 It was therefore crucial to investigate whether
FKBP51 drove permanent pain states across sexes.
2. Material and methods
2.1. Animals
Subjects in all experiments were adult male and female mice (8-12
weeks old). Mice were FKBP51 KO and their WT littermates obtained
from FKBP51 heterozygous from C.A. Dickey’s group (University of
South Florida). These mice were from mixed genetic background,
C57Bl/6J and Swiss Webster. All animals were kept in their home
cages in a temperature-controlled (20 6 1˚C) environment, with
a light–darkcycleof 12hours (light onat 7:30AM); foodandwaterwere
provided ad libitum. All efforts weremade tominimise animal suffering
and to reduce the number of animal used (UK Animal Act, 1986).
2.2. Genotyping
For genotyping, DNA was extracted from a small portion of ear
tissue. Each sample was lysed in 75 mL of alkaline lysis buffer
(25 mM NaOH, 0.2 mM EDTA, pH 12) and heated at 95˚C for 30
minutes. After cooling, 75 mL of neutralising reagent (40 mM Tris-
HCl, pH 5) was added to each sample. The following primers were
used for the polymerase chain reaction (PCR): forward primer (for
WT and 51KO): AAAGGACAATGACTACTGATGAGG; reverseWT
primer: AAGGAGGGGTTCTTTTGAGG; and reverse 51KO primer:
GTTGCACCACAGATGAAACG. Amplification was obtained start-
ing from1mL of DNAand 1 unit of TaqDNApolymerase (Promega,
Madison, WI) in a final volume of 20 mL of amplification buffer.
Fifteenmicroliter of products obtained by amplification was loaded
on a 2% agarose gel containing 20 mL ethidium bromide,
subjected to electrophoresis, and visualized under a UV light.
Samples fromWTanimals showeda single PCRproduct of 363bp;
samples fromKO animals showed a single PCR product of 510bp;
and samples from HET animals presented both bands.
2.3. Pain models
2.3.1. Complete Freud adjuvant–induced ankle joint
inflammation
Inflammation was induced by injection of complete Freud
adjuvant (CFA; Sigma, United Kingdom) at the volume of 5 mL,
in the left ankle joint, under isoflurane anaesthesia induced in
a chamber delivering 2% isoflurane combined with 100% O2 and
maintained during injection using a face mask. The needle
entered the ankle joint from the anterior and lateral posterior
position, with the ankle kept in plantar flexion to open the joint.
Sham treatment consisted of anesthetizing the animals.
2.3.2. Neuropathic model: spared nerve injury
The spared nerve injury (SNI) was performed as previously
described.11,21 Briefly, under isoflurane anaesthesia, the skin on
the lateral surface of the thigh was incised and a section made
directly through the biceps femoris muscle exposing the sciatic
nerve and its 3 terminal branches: the sural, the common
peroneal, and the tibial nerves. The common peroneal and the
tibial nerves were tight ligated with 5-0 silk and sectioned distal to
the ligation. Great care was taken to avoid any contact with the
spared sural nerve. Complete haemostasis was confirmed and
thewoundwas saturated. Sham treatment consisted of exposing
the sciatic nerve only.
2.3.3. Chemotherapeutic-induced neuropathic pain:
paclitaxel
To induce mechanical hypersensitivity, paclitaxel was injected
under isoflurane anaesthesia as previously described.26 Pacli-
taxel (Sigma) was dissolved in a solution made up of 50%
Cremophor EL (Sigma) and 50% absolute ethanol and stored at
220˚C, for a maximum of 14 days, and was diluted in normal
saline (NaCl 0.9%), just before administration. The vehicle for
paclitaxel, 50% Cremophor EL and 50% absolute ethanol, was
diluted, at the time of injection, with saline. Paclitaxel (2 mg/kg)
was injected intraperitoneally (i.p.), on alternating successive
days (days 0, 2, 4, and 6). No weight loss or mortality was
observed in paclitaxel-treated mice throughout the experiments.
2.4. Behavioural testing
N.B: the experimenter was always blind to genotype and
treatment.
2.4.1. Von Frey’s hairs
Animals were placed in Plexiglas chambers, located on an
elevated wire grid, and allowed to habituate for at least 1 hour.
After this time, the plantar surface of the paw was stimulated with
a series of ascending forces Von Frey’s monofilaments. The
threshold was determined using the up-down method as
described by Chaplan et al.10 The data were expressed as log
of the mean of the 50% pain threshold 6 SEM.
2.5. Intrathecal injections
The intrathecal injections were performed as previously de-
scribed.21 Briefly, under anaesthesia, mice were held firmly, but
gently, by the pelvic girdle using the thumb and forefinger of the
nondominant hand. This grip caused the hind legs to splay
outward and downward. The skin above the iliac crest was pulled
tautly to create a horizontal plane where the needle was inserted.
Using the other hand, the experimenter traced the spinal column
of the mouse, rounding or curving the column slightly to open the
invertebrate spaces. A 30-gauge needle connected to a 10 mL
Hamilton syringe was used to enter between the vertebrae. After
injection, the syringe was rotated and removed and posture and
July 2018·Volume 159·Number 7 www.painjournalonline.com 1225
locomotion were checked. All intrathecally delivered drugs were
injected in a 2 mL volume.
2.6. Drugs
Mifepristone (1 nmol in 2mL) was purchased from Sigma andwas
dissolved in 10% ethanol in saline. Control animals received 2 mL
of 10% ethanol in saline. SAFit2 was synthesized as previously
described14 and used at a concentration of 2 mg/mL in vehicle A
(4% ethanol, 5% PEG400, and 5% TWEEN 80 in 0.9% saline;
used at 10 mL/kg or 20 mg/kg) or 10 mg/mL in vesicular
phospholipid gel (VPG) 5 vehicle B (50% (m/m) egg lecithin
containing at least 80% phosphatidylcholine in 10 mM
phosphate-buffered saline (PBS) pH 7.4; used at 10 mL/kg or
100 mg/kg) or in vehicle C (20% EtOH, 40% PPG, 5% PEG400,
and 5% TWEEN 80 in 0.9% saline; used at 10 mL/kg or 100
mg/kg). Vesicular phospholipid gels (with and without SAFit2)
were prepared by a dual asymmetric centrifugation (DAC)
technique as described below. Egg lecithin (Lipoid E80) was
a kind gift from Lipoid GmbH (Ludwigshafen, Germany). Control
animals received vehicle only.
2.6.1. Preparation of vesicular phospholipid gels by dual
asymmetric centrifugation
Vesicular phospholipid gels with a phospholipid amount of 50%
(m/m) were prepared by DAC. To encapsulate the poorly water-
soluble SAFit2 into the formulation by a direct incorporation
method, the accurately weighted phospholipid was solved in
ethanol (100%) and SAFit2 stock solution (20.0 mg/mL in 100%
ethanol) was added in the desired amount to the phospholipid
solution. The ethanol was evaporated for 2 days in a vacuum
drying oven at a temperature of 25˚C and a pressure of 10 mbar.
Then, the solid mixture was hydrated with the accurate amount of
10 mM PBS buffer pH 7.4 and homogenized by a DAC
(Speedmixer DAC 150.1 FVZ; Hauschild GmbH &Co KG, Hamm,
Germany).
Dual asymmetric centrifugation is a double centrifugation
technique which is perfectly suited for themixing of highly viscous
formulations and has been used in the past to prepare liposomes
and fat emulsions.19,35 Its application to manufacture VPGs has
been first described byMassing et al.22 in 2008. In this technique,
the container is not only spun around the commonly known
centrifugation axis in the middle of the centrifuge but also around
a second axis in the middle of the container. Because of the 2
counterrotating movements, high shearing forces and a homog-
enous mixture of the components are achieved.
For homogenization of the phospholipids and buffer in our
study, a process speed of 3500 rpm was used. A custom-made
cooling system was installed to prevent the material from heating
during the continuousmixing over 45minutes. The final amount of
SAFit2 in the formulation was 10 mg/g.
The described manufacture process was used for the
preparation of a second VPG formulation without the addition of
SAFit2 stock solution as a control formulation (vehicle B).
2.6.2. Preparation of an SAFit2 solution with a concentration
of 10 mg/mL
A nonretarded SAFit2 control solution was prepared to evaluate
the depot effect of SAFit2-VPG. Therefore, vehicle C (20%
ethanol, 40% propylene glycol, 5% polyethylene glycol 400%,
and 5% Tween 80 in 0.9% saline) was needed to allow dissolving
SAFit2 in a concentration of 10mg/mL.Using this formulation, the
direct comparison of the subcutaneous injection of the exact
same dose and injection volume of SAFit2 solution and SAFit2-
VPG was possible.
2.7. Blood sampling and corticosterone assay
Bloodwas collected in themorning between 9:00 and 11:00 from
the mouse tail vein. Before sampling, mice were placed in
a warming cabinet (39˚C for 10-15 minutes) to dilate the blood
vessel. The levels of corticosterone were measured using an
ELISA kit (ab108821; Abcam, Cambridge, United Kingdom)
following the manufacturer protocol.
2.8. Fresh tissue collection and RNA preparation
For fresh tissue collection, animals were terminally anesthetized
with CO2 3 days after CFA or sham surgery. The spinal cord
segment corresponding to the lumbar area was rapidly removed,
and the ipsilateral dorsal horn quadrants L4 to L6 were dissected
out and frozen on dry ice. Samples were then stored at 280˚C
until further processing. Total RNA was extracted using an acid
phenol extractionmethod (TRIzol reagent, RNeasymini-columns;
Quiagen, United Kingdom). RNA concentration was measured
using the Nanodrop (Labtech International, Ringmer, United
Kingdom).
2.9. RTqPCR
RNA samples were treated with DNase I (Quiagen, Crewley,
United Kingdom). Equal amounts (between 200 and 500 ng
depending on the set of experiments) of total RNA were reversed
transcribed using random nonamers (Sigma, Poole, United
Kingdom), Oligo (dT) 20 primers (Promega), and Superscript
TM III RT (Invitrogen, Carlsband, CA) for 1 hour at 50˚C in a total
reaction volume of 20 mL. cDNAs were immediately used for
qPCR or kept at 220˚C; qPCR reactions were performed with
DNA Engine (BioRad, Hercules, CA) using SYBR Green
JumpStart Taq ReadyMix (Sigma, Poole, United Kingdom) and
gene-specific primer sets (primer sequences available on re-
quest). One microliter of cDNA diluted 1/10 in H2O was amplified
in a 3-step cycling program in a final reaction volume of 25 mL.
Control cDNA samples obtained without transcriptase were
always included, as well as samples without any cDNA template.
Reactions were performed at least in triplicate and the specificity
of the products was determined by melting curve analysis. The
ratio of the relative expression of target genes to b-actin was
calculated using the 2DCt formula. Efficiencies of qPCRs were
calculated for each gene using serial dilution.
2.10. Immunohistochemistry
For immunohistochemistry, mice were deeply anesthetized with
pentobarbital and perfused transcardially with saline containing
5000 IU/mL heparin followed by 4% paraformaldehyde in 0.1 M
phosphate buffer (PB; 25 mL per adult mouse). Lumbar spinal
cords were dissected out, postfixed in the same paraformalde-
hyde solution for 2 hours, and transferred into a 30% sucrose
solution in PB containing 0.01% azide at 4˚C, for a minimum of 24
hours. Spinal cords were cut on a freezing microtome set
at 40 mm.
For fluorescent immunohistochemistry, sections were left to
incubate with primary antibodies O/N at room temperature (anti-
FKBP51, 1:5000, Santa-Cruz #sc11518; anti-IL6, 1:5000,
Abcam #ab6672). Appropriate biotinylated secondary antibody
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was used at the concentration of 1:400 and left for 90 minutes.
Sections were then incubated with avidin biotin complex (ABC
Elite, Vector Lab; 1:250 Vectastain A plus 1:250 Vectastain B) for
30 minutes followed by a signal amplification step with
biotinylated tyramide solution (TSA; 1:75 for 7 minutes; Perkin
Elmer, Wellesley, MA). Finally, sections were incubated with FITC
avidin for 2 hours (1:600). For multiple labelling, other primary
antibodies were left O/N at room temperature at the end of the
TSA protocol (anti-Iba1 1:1500; Wako, Osaka, Japan; anti-GFAP
1:4000, DAKO, Cambridge, United Kingdom; anti-NeuN: 1:1000)
and revealed the following day with appropriate direct secondary
antibody at a concentration of 1:500 (Alexa Fluor). Finally,
sections were incubated with the acid nucleic marker To-pro,
as per manufacturer instructions. All fluorescent sections were
coverslipped with Gel Mount AqueousMountingMedium (Sigma)
to protect the fluorescence from fading and stored in dark boxes
at 14˚C.
For b-galactosidase and DAB staining, spinal cords were
sectioned on a freezing microtome set to 20 mm. Free-floating
sections were incubated in warmed X-gal working solution (X-gal
stock; X-gal, Chem-Cruz #sc280488, in dimethylformamide;
diluted in X-gal dilution buffer; 5 mM potassium ferricyanide
crystalline, 5 mM potassium ferricyanide trihydrate, and 2 mM
magnesium chloride in PB; 1:40) at 37˚C for 1.5 hours. After the
stain, the sections were washed in PB and then water for 5
minutes each. To achieve double labelling, 3,39-diaminobenzi-
dine (DAB) staining was used. First, the sections were blocked in
PB with 3% serum, 3% triton, and 2% H2O2 for 1 hour, and then
incubated in the chosen primary antibody either O/N (anti-NeuN,
1:1000, Millipore #MAB377; anti-NG2, 1:500, Millipore
#MAB5384; anti-APC, 1:200, Calbiochem #OP80) or for 72
hours (anti-Iba1, 1:500;Wako). The sectionswere then incubated
in appropriate secondary antibodies at 1:500 for 2 hours,
followed by incubation with avidin biotin complex (ABC Elite,
Vector Lab; 1:1000 Vectastain A plus 1:1000 Vectastain B) for 1
hour. The substrate was then developed using a peroxidase
substrate DAB kit (Vector #SK4100) at optimised times, and the
sections were washed and mounted. The following day, the
sections were dehydrated in increasing ethanol concentrations
(70%, 70%, 95%, 95%, 100%, 100%, histoclear 32) and
coverslipped with DPX. For the FKBP51 double DAB labelling,
the sections underwent an initial DAB staining with a chosen
primary antibody, as previously described. The sections were
then incubated in anti-FKBP51 (1:500, Santa-Cruz #sc11518) for
72 hours and a second DAB staining procedure was completed,
with the addition of a Nickel solution to the substrate mixture, to
produce the distinguishable gray stain.
2.11. Image analysis
2.11.1. Fluorescent images: confocal imaging and analysis
All fluorescent images of quadruple stain tissue were acquired by
confocal microscopy using a laser-scanning microscope (Leica
TCS NT SP). Sequential laser channel acquisition was used to
prevent the generation of false positives by “bleed through” of
immunofluorescence from 1 channel to the other. For quantitative
analysis of cell-specific expression of FKBP51, single plan images
were acquired with an ACS APO 40.0x oil objective (Figs. 2B and
C). A single picture per section side was taken spanning laminae I
to III. Offset, gain, and laser strength of each scan was not
changed throughout the imaging. Five dorsal horn sections were
imaged per animal for each ipsilateral and contralateral side, n5
3/group. Cell-specific expression was manually quantified from
confocal images and individual optical plan inspection. For a cell
(neurone, astrocyte, or microglia) to be considered positive for
FKBP51, the expression of FKBP51 had to appear together with
the cell-specific marker (or surrounded by the cell-specific marker
for Gfap), and with the nucleic acid stain To-pro which labels all
nuclei. We quantified the number of neurones, astrocytes, and
microglia positive for FKBP51 and expressed it as a percentage of
total number of neurones, astrocytes, or microglia.
2.11.2. b-Galactosidase and DAB images
Images of b-galactosidase and DAB tissue were acquired using
a Zeiss Axio Scan Z1 Slide Scanner bright field microscope. This
would not allow the dissection of individual optical channels.
Entire spinal cord sections were imaged using this system, with 5
to 6 dorsal horn sections imaged per animal, n 5 3/group. Cell-
specific expression was manually quantified from acquired
images. For a cell (neurone or microglia) to be considered positive
for FKBP51, X-gal stain had to appear within the cell-specific
marker (NeuN or Iba1). We quantified the number of neurones
and microglia positive for FKBP51 and expressed it as
a percentage of total number of neurones or microglia.
2.12. Data analysis
All statistical tests were performed in IBM SPSS statistic 20. For
the behavioural experiments, statistical analysis was performed
on the data normalized by log transformation (Von Frey data; as
suggested by Mills et al.25). The significance of any differences in
sensitivity was assessed using repeated-measured 2-way or
1-way analysis of variance (ANOVA), as appropriate. In all cases,
a significant effect of the main factor(s), or interactions between
them, was taken as the criterion for progressing to post hoc
analysis. Bonferroni analysis was the preferred post hoc analysis;
however, if the general ANOVA was significant but no Bonferroni
significance observed, we also reported the results of the least
significant difference post hoc analysis. In all cases, “time” was
treated as a within-subjects factor and “genotype” and “treat-
ment” were treated as between-subject factors. For the RTqPCR
experiments, data were analysed by univariate analysis for
individual genes followed by the appropriate post hoc analysis
(1-way ANOVA or t test). Biological samples for the measures of
glucocorticoid levels were analysed by 2-way ANOVA and
appropriate post hoc analysis.
2.13. Study approval
All procedures described in this article comply with the UK
Animals (Scientific Procedures) Act 1986 and the research was
performed under strict HomeOffice regulations, under the project
licence PPL 70/7944.
3. Results
3.1. FKBP51 deletion significantly attenuates the
development of mechanical hypersensitivity in long-term
pain states across sexes
3.1.1. Inflammatory pain states
We first examinedwhether FKBP51 regulated the development of
themechanical hypersensitivity seen with ankle joint inflammation
in femalemice throughmodulation of glucocorticoid signalling, as
we have reported in male mice.21 We first tested the effect of
global deletion of FKBP51 on themechanical hypersensitivity that
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develops after the injection of CFA in the ankle joint. Global
deletion of FKBP51 in female mice did not affect their basal
mechanical threshold when compared with WT mice (Fig. 1A).
However, after CFA injection in the ankle joint, although both WT
and KO mice showed a significant decrease in mechanical
sensitivity, the effects observed in KOmice were significantly less
severe than in WT mice (Fig. 1A), as previously observed in
males.21
Next, using RT-qPCR, we measured a significant increase in
spinal FKBP51 mRNA in WT female mice after induction of joint
inflammation with CFA (Fig. 1B), consistent with our previous
findings.21 This increase was accompanied by an upregulation of
IL6 and of the GR isoform associated with glucocorticoid
resistance,20 GRb (Fig. 1B), suggesting that glucocorticoid
signalling was likely to contribute to the development of this
long-term pain state in females, as seen in males.
Crucially, FKBP51 and IL6 were not upregulated in the dorsal
horn of mice after IL6 injection in the hind paw (for FKBP51: sham
1006 7 vs IL6-treated ipsi: 1206 21; for IL6: sham 1006 14 vs
IL6-treated ipsi: 1496 41; mean6 SEM, 24 hours post IL6, data
normalised to WT; n 5 6/6). Injection of IL6 in the hind paw
induces short-term inflammation which is not modulated by
FKBP51 (no differences in behaviour between FKBP51 KO and
WT mice), but induces a mechanical hypersensitivity of a similar
degree than that seen with ankle joint inflammation.21
Finally, we tested the hypothesis that glucocorticoid signalling
contributes to the development of CFA-induced joint pain in
female mice and investigated whether FKBP51 regulation of this
pain state occurred through the modulation of glucocorticoid
signalling. For this, we used the GR antagonist mifepristone
(RU38486). When mifepristone was administered intrathecally 3
days after CFA injection in the ankle joint, there was a rapid
reduction in the CFA-induced hypersensitivity in WT mice (Fig.
1C), indicating that GR signalling was crucial to the full
manifestation of the hypersensitivity. However, we observed an
increase in the hypersensitivity in FKBP5 KO mice after
mifepristone (Fig. 1C), indicating that, after FKBP5 deletion, GR
signalling in long-term pain states was antinociceptive. All
together, these results were consistent with our findings in males
and demonstrated that FKBP51 regulates inflammatory pain states
in a sex-independent manner and, at least partly, by modulating
GRsignalling andpossibly through the regulationof IL6 expression.
Supporting this idea,weobserved that IL6wasmainly expressed in
neurones in the superficial dorsal horn ofmicewith an inflamed joint
(Fig. S1, available online as supplemental digital content at http://
links.lww.com/PAIN/A550), as we had previously reported for
FKBP51.21
3.1.2. Nerve injury
We next investigated whether FKBP51 also regulated neuro-
pathic pain states across sexes. Both KO male and KO female
mice were less sensitive than their sex-matchedWT littermates to
neuropathic pain induced by SNI11 (Fig. 2A). There was no
difference between females and males mechanical thresholds
both at baseline and after surgery.
To explore the effects of the deletion of FKBP51 on GR
signalling, wemeasured corticosterone levels in KO andWTmice
before and after SNI, as we had performed previously in a model
of ankle joint inflammation.21 We found that nerve injury induced
an overall increase in plasma corticosterone levels across both
genotypes (Table 1), but that plasma corticosterone levels were
lower in KO mice both before and after nerve injury (Table 1),
Figure 1. FKBP51 regulates long-term joint inflammatory pain states in female mice bymodulation of glucocorticoid signalling. (A) Mechanical sensitivity in female
knock-out (KO) and wild-type (WT) mice after injection of CFA in the ankle joint (n5 8/8) (2-way analysis of variance (ANOVA), TIME B3 to D14, factor “Genotype”:
F1,14 5 11.3, P , 0.01). B: Baseline; D: day. Data show mean 6 SEM. *P , 0.05, **P # 0.01, WT vs KO; post hoc 1-way ANOVA. (B) RT-qPCR analysis of
FKBP51, IL6, and GRb in the dorsal horn 3 days after CFA injection in the ankle joint; data normalized to WT sham (for FKBP51 data, ANOVA: F2,185 3.53; P,
0.05; post hoc analysis least significant difference (LSD) P, 0.05. For GRb data, ANOVA: F2,185 3.44; P, 0.05 post hoc analysis LSD P, 0.05. For IL6 data,
ANOVA: F2,185 2.72; P, 0.1; post hoc analysis LSD P, 0.05). Data show mean6 SEM. *P, 0.05. (C) RU38486 (mifepristone, GR antagonist) effect on CFA-
induced mechanical hypersensitivity in female WT mice and female KO mice (n 5 4/7). Wild-type/vehicle vs WT/RU38486: 2-way ANOVA, 1 h-D4, factor
“Treatment”: F1,95 5.4, P, 0.05; KO/vehicle vs KO/RU38486: 2-way ANOVA, TIME B2 to 1 hour, factor “Treatment”: F3,185 3.3, P, 0.05. B: Baseline; D: day.
Data show mean 6 SEM. *P , 0.05: WT/vehicle vs WT/RU38486; #P , 0.05: KO/vehicle vs KO/RU38486; results of post hoc 1 way ANOVA. CFA, complete
Freud adjuvant; GR, glucocorticoid receptor; IT, intrathecal.
Table 1
Corticosterone levels in FKBP5 KO and WT mice before and
after nerve injury.
Naive 5 days after SNI 14 days after SNI
FKBP5 KO 116.4 6 40.5* 322.4 6 122.9 113.7 6 34.1†
WT 217.0 6 27* 465.8 6 54.5‡ 522.8 6 183.5†‡
Plasma corticosterone levels are expressed in ng/mL. Data show mean 6 SEM. Two-way ANOVA, factor
genotype F1,15 5 11.3, P , 0.01; factor “Time” F2,15 5 4.8, P , 0.05; post hoc analysis: LSD. Female
mice. N 5 2 to 4.
* P , 0.05, WT vs KO within each time point.
† P , 0.01, WT vs KO within each time point.
‡ P , 0.05: vs naive within each genotype.
ANOVA, analysis of variance; KO, knock-out; LSD, least significant difference; SNI, spared nerve injury; WT,
wild-type.
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Figure 2. FKBP51 regulates neuropathic pain states across sexes and is often seen in neurones and sometimes in astrocytes in the superficial dorsal horn. (A)
Mechanical sensitivity in female and male KO and WT mice after SNI (n5 6 per group) (2-way analysis of variance [ANOVA], TIME D1 to D14, factor “Genotype”:
F1,195 39.6,P, 0.0001. Two-way ANOVA female only, TIMED1 toD14, factor “Genotype”: F1,95 21.4,P, 0.001. Two-way ANOVAmale only, TIMED1 toD14,
factor “Genotype”: F1,105 17.8,P, 0.01) *P,0.05, **P,0.001,
#P,0.05, ##P,0.001. (B andC) FKBP51 immunoreactivity 7 days after SNI surgery. FKBP51was
often seen in neurones (stained with NeuN, blue, B and C), sometimes in astrocytes (stained with Gfap, red, B), and very rarely in microglia (stained with Iba1, red,
C). (B andC) Cyan: To-pro, nuclear marker; scale bar: 15mm. Arrows indicate astrocytes ormicroglia positive for FKBP51; arrowheads indicate microglia negative
for FKBP51. (D–G) X-Gal stain confirming that FKBP51 (blue) is mainly expressed in neurones (brown, D and E) and very rarely in microglia (brown, F and G). Scale
bar: 100 mm; arrows indicate neurones or microglia positive for X-gal; arrowheads indicate microglia negative for FKBP51. KO, knock-out; SNI, spared nerve
injury; WT, wild-type.
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confirming our observation that FKBP5 deletion leads to the
suppression of corticosterone secretion both in naive mice and
mice with persistent pain.21
We then wanted to characterise FKBP51 protein expression in
mice with nerve injury, specifically in the superficial dorsal horn,
where FKBP51 exerts its key role in themodulation of mechanical
hypersensitivity.21 We had previously reported that FKBP51 was
mainly expressed in neurons of the superficial dorsal horn of mice
and rats that were naive or had an inflamed joint15,21 and this was
supported by others.6 However, FKBP51 mRNA has also been
found in cultured brain microglia.42 Because astrocytes and
microglia are activated in the superficial dorsal horn after nerve
injury, tissue from SNI animals was particularly suited to
investigate the expression of FKBP51 in these cell types. Using
a protocol of amplification with tyramide and an antibody from
Santa Cruz that showed no specific stain in FKBP51 KO mice,21
we fully characterised the expression of FKBP51 in the superficial
dorsal horn of mice. FKBP51 expression was mainly seen in
neuronswith 58%6 4%of neurones expressing FKBP51 in naive
mice and 44% 6 5% of astrocytes, or 6 FKBP51-positive
neurones for every FKBP51-positive astrocyte (Fig. 2B). After
nerve injury (7 days postsurgery), there was a significant increase
in the proportion of neurones and astrocytes expressing FKBP51,
with FKBP51 seen in 70%6 5% of neurones on the injured side
(F1,45 14.6,P, 0.05) and 60%6 5%of astrocytes (F1,45 9.2,P
, 0.05), or 7 FKBP51-positive neurones for every FKBP51-
positive astrocyte. Microglia very rarely stained positive for
FKBP51, with an average of 7% 6 5% of microglia positive for
FKBP51, or 117 FKBP51-positive neurones for every FKBP51-
positive microglia (Fig. 2C), and no increase after nerve injury.
There was no difference in the number of neurones, astrocytes,
and microglia expressing FKBP51 between male and female
mice (data not shown). To confirm the low level of expression of
FKBP51 in microglia, we used an X-Gal stain. The FKBP5 KO
mice contain a b-galactosidase reporter cassette which
expresses wherever the FKBP5 gene is normally expressed.
Using this approach, we found that the gene FKBP5 was
expressed in 85% 6 1.5% of neurones and in 5% 6 1% of
microglia in the dorsal horn of SNI mice (Figs. 2D–G).
Altogether, our data suggested that FKBP51 contributes to the
development and maintenance of mechanical hypersensitivity
after nerve injury across sexes, and although FKBP51 is mainly
expressed in neurones, astrocytic mechanisms of FKBP51-
driven nociceptive signalling cannot be excluded.
3.1.3. A model of chemotherapy-induced pain
Here, we sought to investigate the involvement of FKBP51 in
a pathological pain model induced by the chemotherapeutic drug
paclitaxel. Paclitaxel treatment induced a significant decrease in
mechanical sensitivity in adult mice (Fig. 3A) compared with
vehicle. However, the effects observed in KO mice were
significantly less severe than in WT mice (Fig. 3B), indicating that
FKBP51 drives paclitaxel-associated mechanical
hypersensitivity.
At the molecular level, we found that the paclitaxel-associated
hypersensitivity was accompanied by an increase in FKBP51
expression in the superficial dorsal horn and an increase in GRb
expression and IL6 (Fig. 3C), as observed in inflammatory pain
states (Fig. 1B)21 and after peripheral nerve injury.44
3.2. Pharmacological inhibition of FKBP51 significantly
attenuates mechanical hypersensitivity in established long-
term pain states
Finally, we characterised the effect of pharmacological blockade
of FKBP51 using the only specific ligand available for in vivo use,
the FKBP51 ligand SAFit2.1,14,17 We have previously shown that
1 single intrathecal administration of SAFit2 (4 mg in 2 mL) could
reduce the hypersensitivity induced by ankle joint inflammation in
male mice for 4 hours.21 Here, we explored the efficacy of various
routes of administration of SAFit2 on established long-lasting pain
states across sexes.
A single i.p. injection of SAFit2 (20 mg/kg) was able to reduce
injury-induced mechanical hypersensitivity when injected when
the pain state was fully developed 3 days after CFA injection in the
ankle joint (Fig. 4A) or 5 days after SNI surgery (Fig. 4B). As
expected, the effect of a single injection of SAFit2 lasted no more
than 8 hours in both models, and we decided to test the effect of
repeated injections of SAFit2 (20 mg/kg), twice daily, over 4 days.
After this protocol, SAFit2 significantly reduced the injury-induced
hypersensitivity for up to 4 days in the joint inflammatory and
neuropathic models (Figs. 4C and D).
To reduce animal stress and improve the efficacy of the drug
treatment, we explored a state-of-the art method of sustained
release of FKBP51 using VPGs.1 Here, SAFit2-VPG was injected
subcutaneously 5 days (Fig. 4E) after SNI surgery (SAFit2
100 mg/kg). A single injection of SAFit2-VPG reduced the
SNI-induced mechanical hypersensitivity for at least 7 days.
Comparing the subcutaneous unretarded delivery of an SAFit2
Figure 3. FKBP51 regulates the mechanical hypersensitivity seen in a model of paclitaxel-induced pain. (A) Mechanical sensitivity in wild-type (WT) mice after
paclitaxel or vehicle treatment (n5 7/5) (2-way analysis of variance [ANOVA], TIMED4 toD8, factor “Treatment”: F1,105 6.6,P, 0.01). (B)Mechanical sensitivity in
male KO andWTmice after paclitaxel treatment (n5 6/6) (2-way ANOVA, TIMED1 to D12, factor “Genotype”: F1,105 34.8,P, 0.0001). Data showmean6SEM.
*P , 0.05, **P , 0.01, ***P , 0.001, results of post hoc 1-way ANOVA. (C) RT-qPCR analysis of FKBP51, IL6, and GRb in the dorsal horn 10 days after PTX
injection (n 5 5/5); data normalized to WT sham; *P , 0.05.
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Figure 4. Pharmacological blockade of FKBP51 reduces the mechanical hypersensitivity seen in long-term pain states in both male and female mice. (A) Single
subcutaneous injection of SAFit2 3 days after CFA in the ankle joint inWTmales (n5 4/4) (2-way analysis of variance [ANOVA], TIMED3 to 28 h, factor “Treatment”:
F1,55 21.6, P, 0.01). (B) Single subcutaneous injection of SAFit2 5 days after spared nerve injury (SNI) in males (n5 4/4) (2-way ANOVA, TIME D5 to D7, factor
“Treatment”: F1,65 7.98, P, 0.05). (C) Repeated systemic i.p. injection of SAFit2 3 days after CFA in the ankle joint in males (n5 6/8) (2-way ANOVA, TIME D1 to
D11, factor “Treatment”: F1,125 6.8, P, 0.05). (D) Repeated systemic i.p. injection of SAFit2 5 days after SNI in males (n5 6/8) (2-way ANOVA, TIME D1 to D13,
factor “Treatment”: F1,125 8.8,P, 0.05). Intraperitoneal injections in (C andD): SAFit2 2mg/mL in vehicle A. (E) Single subcutaneous injection of SAFit2-VPG (n5
5/5) in females (SAFit2 10 mg/mL, 10 mL/kg in vehicle B) 5 days after SNI (2-way ANOVA, TIME D7 to D13, factor “Treatment”: F1,85 17.1, P, 0.01). (F) Single
subcutaneous injection of SAFit2 5 days after SNI in females (n5 4/4) (2-way ANOVA, TIMED5 to D7, factor “Treatment”: F1,65 6.0,P, 0.05) (SAFit2 10mg/mL,
10mL/kg in vehicle C). (G) Single subcutaneous injection of SAFit2-VPG in naiveWTmice. (H) Single subcutaneous injection of SAFit2-VPG 3 days after CFA in the
ankle joint in KOmice. (G and H) N5 3 per group. (I) Single subcutaneous injection of SAFit2-VPG (n5 6/6) in male after paclitaxel (SAFit2 10mg/mL, 10mL/kg in
vehicle B) (2-way ANOVA, TIME D14 to D20, factor “Treatment”: F1,10 5 10.3, P , 0.01). Arrows indicate intraperitoneal injections: pointing-down arrows,
paclitaxel injection; pointing-up arrow, SAFit2-VPG. (J) Repeated subcutaneous injection of SAFit2-VPG (n5 8/8) inmales 12 days after SNI (SAFit2 10mg/mL, 10
mL/kg in vehicle B). SAFit2-VPGwas injected onD12 andD19; (2-way ANOVA, TIMED15 to D26, factor “Treatment”: F1,65 48.3,P, 0.001). (A–J) B: baseline; D:
day. (E, F, I and J): the purple band highlights a period of 5 days starting 48 hours after SAFit2 injection. Data show mean6 SEM. *P, 0.05, **P, 0.01, ***P,
0.001, results of post hoc 1-way ANOVA. SAFit2 or vehicle injection time is indicated by vertical arrows (small arrow for SAFit2 and big arrow for SAFit2-VPG). CFA,
complete Freud adjuvant; i.p., intraperitoneal; KO, knock-out; VPG, vesicular phospholipid gel; WT, wild-type.
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solution containing the same dose of SAFit2 (SAFit2 100 mg/kg)
(Fig. 4F), we could confirm the depot effect of the VPG and the
slow release of SAFit2 from the liposome matrix by diffusion,
leading to a significantly sustained pharmacological effect of
SAFit2. SAFit2-VPG had no effect in naive mice (Fig. 4G),
confirming that FKBP51 did not regulate naive mechanical
threshold nor in CFA-injected FKBP5 KO mice (Fig. 4H),
confirming the specificity of the ligand SAFit2.
We then tested if SAFit2 could improve the mechanical
hypersensitivity that develops after PTX treatment. Mice received
a single injection of SAFit2-VPG (SAFit2 100 mg/kg) 12 days after
the first injection of PTX, when the mechanical hypersensitivity
was fully established. As expected, SAFit2-VPG significantly
reduced the mechanical hypersensitivity for at least 5 days
(Fig. 4I).
Finally, we investigated whether delayed administration of
SAFit2-VPG could improve long-term pain states that had been
fully established for at least 1 week and whether repeated
administration of SAFit2-VPGwould maintain the improvement of
the pain state. When given 12 days after nerve injury, SAFit2-VPG
(SAFit2 100 mg/kg) once again reduced the SNI-induced
mechanical hypersensitivity and when the injection was repeated
7 days after the first one, the reduced hypersensitivity was
maintained for at least 16 days (Fig. 4J). Altogether, our data
strongly suggest that FKBP51 is a promising pharmacological
target for the treatment of persistent pain states across sexes.
4. Discussion
In this study, we have demonstrated that FKBP51 was the driver
of long-term pain states of varied aetiology but all associated with
the upregulation of IL6 at spinal cord level. This regulation of
persistent pain states by FKBP51 was seen across sexes and
occurred through modulation of glucocorticoid signalling. Then,
using the unique FKBP51 ligand for in vivo use, SAFit2,
encapsulated in a state-of-the-art VPG for slow release, we have
shown that pharmacological inhibition of FKBP51 reduced the
established mechanical hypersensitivity induced by joint in-
flammation, nerve injury, and the anticancer drug paclitaxel. We
therefore propose that FKBP51 is a new pharmacologically
tractable target suitable for the treatment of persistent pain in
both males and females.
Here, we demonstrated that FKBP51 drives long-term pain
states across sexes and established that a pharmacotherapy
targeting FKBP51 would alleviate long-lasting pain states in
males and females. This was a very important translational step
forward because themechanisms of development of chronic pain
states differ between sexes and sex differences in analgesic
response to pain treatment are often seen.2,32 Our data, however,
suggest that pharmacological inhibition of FKBP51 is sufficient to
improve the mechanical sensitivity that develops in a variety of
long-term pain states in both female and male mice. It is currently
understood that sex differences observed in chronic pain states
arise from differences in immune system between males and
females. Immune cells are known to contribute to the de-
velopment of chronic pain, and microglial–neurones interactions,
in particular, have been believed to be crucial to the establishment
of long-lasting pain states.3,37,41 However, although males and
females show similar microglial activation in the superficial dorsal
horn after injury, females are not reliant on this activation for the
development of mechanical hypersensitivity while males are.31,34
Our observation that FKBP51 is mainly expressed in neurones
and hardly ever seen in microglia in the spinal cord would argue
that the mechanisms of regulation of persistent pain states by
FKBP51 are independent of immune cells–related events that
often precede neuronal changes at spinal cord levels in chronic
pain states.
At the molecular level, we found that the persistent pain states
that were driven by FKBP51 were associated with (1) changes in
glucocorticoid signalling, as indicated by the increased expres-
sion at spinal cord level of GRb, the GR isoform associated with
glucocorticoid resistance20,28 and increased levels of plasma
corticosterone, and (2) an upregulation of IL6 expression in the
dorsal horn, as shown by our data and work from others recently
reviewed by Zhou et al.44 Although the requirement for intact GR
signalling for the full development of persistent pain states has
already been established,33,39,40 the downstream events that
drive these pain states are not fully understood. The N-methyl-D-
aspartate (NMDA) receptor was found upregulated in the spinal
cord after chronic constriction nerve injury and had been
suggested as a crucial link between GR signalling and persistent
neuropathic pain induced by chronic constriction nerve injury.40
However, we found no changes in expression of the NMDA
receptor after inflammation of the ankle joint (data not shown) at
a time point where FKBP51 was upregulated and mice
hypersensitive. These results suggested that the NMDA receptor
was unlikely to be central to the mechanisms of maintenance of
persistent pain by FKBP51. However, our findings that IL6 was
upregulated in the 3 pain models we have studied suggest that
IL6 could be a crucial link. Administration of IL6 can cause
mechanical allodynia and intrathecal injection of anti-IL6 neutral-
izing antibody can alleviate pain-related behaviours,24,44 in-
dicating a critical role for IL6 in the maintenance of persistent
pain states. Because GR can directly regulate IL6 transcription by
complex binding to IL6 promoter regulatory elements38 and
because the GR agonist dexamethasone can induce IL6
expression in rodent neurons,27 it is possible that the regulation
of chronic pain states by FKBP51 occurs through IL6, down-
stream of glucocorticoid signalling. The fact that FKBP51 and IL6
are mainly expressed in neurones in the superficial dorsal horn
would support this idea. Importantly, injured FKBP5 KOmice had
lower levels of IL6 in the superficial dorsal horn after CFA injection
in the ankle joint21 and after nerve injury (data not shown).
Moreover, IL6 is not upregulated in the dorsal horn in short-term
pain states that are not modulated by FKBP51, such as the
inflammatory pain state initiated by IL6 injection in the hind paw.21
Although the regulation of IL6 expression in the dorsal horn by
glucocorticoid signalling remains to be demonstrated, our data
certainly provide further support for the regulation of persistent
pain states by GR signalling at spinal cord level.
Here, we were able to replicate the effect of FKBP51 deletion
on injury-induced mechanical hypersensitivity using the FKBP51
ligand SAFit2. Using the same doses of SAFit2 in vivo (20 mg/kg
or 100 mg/kg for SAFit2-VPG), others were also able to replicate
the anxiolytic properties, FKBP51 deletion17 and its effects on
body weight regulation and glucose tolerance.1 This study also
showed that high and stable SAFit2 plasma levels can be
achieved in vivo, and that the slow release SAFit2-VPG
formulation reaches plasma SAFit2 concentrations comparable
with the repeated-twice daily 20 mg/kg injection.1 Importantly,
SAFit2 has a selectivity for FKBP51 over FKBP52.10,00014 and
a .5003 selectivity windows for a panel of 43 behaviourally
relevant central nervous system receptors (https://pdspdb.unc.
edu/pdspWeb; unpublished data Dr Felix Hausch). Although the
FKBP51 functions modulated by SAFit2 currently remain unclear,
our data could suggest that SAFit2modulates FKBP51 regulation
of GR sensitivity. Whether SAFit2 can reverse the increase in IL6
observed in our animal models also remains to be investigated.
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Crucially, we were able to offer long-lasting pain relief in
persistent pain states, in both male and female mice, using
a single injection of SAFit2 encapsulated in a VPG allowing the
slow release of SAFit2.1 Vesicular phospholipid gels are highly
concentrated, semisolid dispersions of phospholipids in aqueous
medium8 that display excellent biocompatibility because of their
composition of solely phospholipids and water or buffer9 and can
provide release rates over several weeks. Vesicular phospholipid
gels have been used in the past as depot formulations for the
sustained release of pharmaceutical drugs, including peptides
and proteins.9,16,36 The capability of VPGs to encapsulate water-
soluble drugs, as well as drugs with poor solubility in aqueous
medium, makes them perfectly suited as a sustained release
system for a substance such as SAFit2. Hydrophobic interactions
between the relatively lipophilic SAFit2 and the phospholipids of
the formulation lead to binding and incorporation of the drug in the
hydrophobic areas of the phospholipid bilayers of the liposome
matrix, and SAFit2 has to diffuse through several densely packed
hydrophilic and lipophilic compartments on its way out of the
depot, resulting in a strong retardation. Here, SAFit2-VPG was
injected subcutaneously, once the pain states were fully
established, and was able to reduce the mechanical hypersen-
sitivity for at least 7 days after a single injection, and at least 14
days when reinjected after 7 days, indicating that chronic
inhibition of FKBP51 could offer long-lasting pain relief.
SAFit2 resolved mechanical hypersensitivity when adminis-
trated as late as 12 days after nerve injury, suggesting that
inhibition of FKBP51 could be a promising treatment for chronic
pain for patients with late diagnosis. We have also shown that
FKBP51 could be targeted to reduce the hypersensitivity seen in
a murine model of chemotherapy-induced peripheral neuropa-
thy, even when given once the pain state was fully established.
Chemotherapy-induced peripheral neuropathy is a common
debilitating side effect of anticancer drugs and unfortunately, with
no treatment options for chemotherapy-induced peripheral
neuropathy, clinicians often need to reduce the dose of the
chemotherapeutic agent or discontinue its use,30 which leads to
poorer survival rates. Our data suggest that FKBP51 inhibition
could provide pain relief to cancer patients treated with paclitaxel
and therefore offer hope for prolonged anticancer treatments.
5. Conclusions
In conclusion, we have demonstrated that FKBP51 is an exciting
newpharmacological target for the treatment of chronic pain states
across sexes. Inhibition of FKBP51 with the state-of-the-art
ligand SAFit2 reduced the hypersensitivity that develops after
ankle joint inflammation, nerve injury, and paclitaxel treatment.
These long-term pain states have distinct underlying mecha-
nisms, suggesting that FKBP51 could be targeted for the
treatment of a large number of persistent pain states across
sexes. Moreover, when encapsulated in VPG, a single injection
of SAFit2 led to a long-lasting relief of hypersensitivity indicating
a strong translational potential for chronic treatment by FKBP51
inhibition. Importantly, individuals with variants in the FKBP5
gene have altered pain sensitivity after trauma,7 lending
confidence that pharmacological inhibition of FKBP51 could
indeed help patients suffering with chronic pain.
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